Countdown to Interim Analysis, page-90

Its great that you are well informed on Mesoblast, but rather than treat this as a p*ssing contest, why not share with other HC readers your insight?

For those unaware, Mesoblast is partnering with the Cardiothoracic surgical trials networks established by the NIH (National Institues of Health). Presumably thats what bhoulahan means when he says "MSB does not have any data - they are not running the trials"?

"Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-Lwill be formally evaluated in a randomized, placebo-controlledtrial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19).This multi-centerPhase 2/3 trial will be conducted as a public-privatepartnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-Lin the treatment of patients with COVID-19ARDS, and will provide investigational product for the trial.Mesoblast Chief Executive Dr Silviu Itescu stated: "This significant public-private partnership is a prime example of how the combined resources of industry and government can be leveraged to evaluate in a most efficient and rigorous manner the potential of innovative therapies to make a meaningful difference to patient outcomes."CTSN Chairman Dr A. Marc Gillinov said: "We are excited to work with Mesoblast to make a real impact on the high mortality associated with COVID-19. This randomized controlled trial is in line with our mandate to rigorously evaluate novel therapies for public health imperatives.""

Mesoblast does have the data and they are running the trials, in a partnership with the CTSN, which adds a great deal of credibility to the study results when they do come out.